Novinky v léčbě dyslipoproteinemie

Title in English What's new in the treatment of dyslipoproteinemia

SOŠKA Vladimír KYSELÁK Ondřej

Year of publication 2016
Type Article in Proceedings
Conference Aktuality z vnitřního lékařství 2016 : XXIII. kongres České internistické společnosti ČLS J.E. Purkyně, 21.-24.9.2016
MU Faculty or unit

Faculty of Medicine

Field Other specializations of internal medicine
Keywords dyslipidemia; statins; ezetimibe; fenofibrate; PCSK9 inhibitors
Description The first-line class of drugs for the treatment of dyslipidemia continue to be statins, Ezetimibe is a drug used primarily in combination with statins, and a recent interventions! study reported that ezetimibe also reduces the risk of coronary events. A combination of a statin with feaofibrate can be considered when treating individuals with combined dyslipidemia; however, there is only little evidence for this combination regarding its effect on cardiovascular events. A new class of lipid-lowering drugs, which should become available in the Czech Republic within several months, are PCSK9 inhibitors.

You are running an old browser version. We recommend updating your browser to its latest version.

More info